# Rybrevant Faspro

NDC: 57894-514
Generic name: AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT)
Labeler / Manufacturer: Janssen Biotech, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION
Routes: SUBCUTANEOUS
Marketing started: 20251219

FDA application: BLA761433

## Active ingredients

- AMIVANTAMAB: 2240 mg/14mL
- HYALURONIDASE (HUMAN RECOMBINANT): 28000 mg/14mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"57894-514"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=57894-514
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9e58b045-e352-4f62-99bf-77fae1bebc69